UnitedHealth Group's stock has dropped over 50% in 2024 amid operational disruptions and DOJ probes, despite strong ROCE. Insights on regulatory risks, Medicare cost pressures, and valuation outlook for investors.

FG CEO Christopher O Blunt makes significant stock purchase amid Q1 loss; firm focuses on strategic capital allocation and managing margin compression while maintaining asset growth.

TD Cowen lowers UnitedHealth stock rating and price target due to increased risk and regulatory issues in Medicare Advantage and Medicaid sectors, amid ongoing criminal investigation. Brokerages maintain an outperform stance with long-term valuation upside noted.

UnitedHealth Group stock falls sharply as CEO changes and 2025 guidance withdrawal increase uncertainty. Analysis of implications for the health insurance market.

UnitedHealth downgraded to Neutral by BofA after suspending 2025 guidance due to Medicare Advantage challenges. Analyst price targets and ratings vary amid uncertainty.

RLI Corp. reported Q1 earnings beating estimates but revenue missed slightly; cautious outlook persists with negative earnings revision trends in property and casualty insurance sector.

An analysis of F&G Annuities & Life reveals challenges in financial performance and low earnings growth despite profit retention.